Role of Vitamin D Receptor Activators in Peritoneal Dialysis

被引:0
作者
Bover, J. [1 ]
Lloret, M. J.
DaSilva, I.
Furlano, M.
Diaz, M.
Herreros, A.
Cozzolino, M. [2 ,3 ]
Ballarin, J.
机构
[1] Fundacio Puigvert, Dept Nephrol, IB St Pau, ES-08025 Barcelona, Spain
[2] Univ Milan, Div Renal, Fac Med & Chirurg, Dipartimento Med & Chirurg, Milan, Italy
[3] Univ Milan, Lab Expt Nephrol, Fac Med & Chirurg, Dipartimento Med & Chirurg, Milan, Italy
来源
PERITONEAL DIALYSIS - STATE-OF-THE-ART 2012 | 2012年 / 178卷
关键词
CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; NEPHROLOGY SOCIETY RECOMMENDATIONS; MINERAL METABOLISM ALTERATIONS; GROWTH-FACTOR; 23; SECONDARY HYPERPARATHYROIDISM; BONE-DISEASE; VASCULAR CALCIFICATION; MORTALITY RISK; ADYNAMIC BONE;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD), including patients on peritoneal dialysis (PD), is linked to an important increase in mortality risk. Within the new systemic term CKD-MBD, alterations in vitamin D metabolism are also included. Many adverse events have been associated with vitamin D deficiency or lack of vitamin D receptor (VDR) activation both in the general population and CKD patients, and these associations seem to be maintained in PD patients. Particularities of PD in vitamin D metabolism, calcium balance, low PTH levels and the high prevalence of adynamic bone disease are discussed. We also review the associations of clinical or survival benefits with vitamin D supplementation, VDR or selective VDR activation, although they are low-graded and most of them obtained from HD databases. Nevertheless, we think that the combined approach to secondary hyperparathyroidism seems also to be appropriate in PD patients, and vitamin D (native plus VDR or selective VDR activation) seem an important part of the required integral approach. The later may provide additional benefits but definitive prove is still lacking. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:124 / 142
页数:19
相关论文
共 167 条
[1]  
Adragao T, 2008, PERITON DIALYSIS INT, V28, P668
[2]   Low Bone Volume-A Risk Factor for Coronary Calcifications in Hemodialysis Patients [J].
Adragao, Teresa ;
Herberth, Johann ;
Monier-Faugere, Marie-Claude ;
Branscum, Adam J. ;
Ferreira, Anibal ;
Frazao, Joao M. ;
Curto, Jose Dias ;
Malluche, Hartmut H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02) :450-455
[3]   Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].
Agarwal, R ;
Acharya, M ;
Tian, J ;
Hippensteel, RL ;
Melnick, JZ ;
Qiu, P ;
Williams, L ;
Batlle, D .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828
[4]   Vascular calcification in dialysis patients [J].
Al Humoud, H ;
Al-Hilali, N ;
Ahmad, AAMH ;
Ninan, VT ;
Nampoory, MRN ;
Rizk, AM ;
Ali, JH ;
Johny, KV .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (10) :4183-4186
[5]   Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial [J].
Alborzi, Pooneh ;
Patel, Nina A. ;
Peterson, Carla ;
Bills, Jennifer E. ;
Bekele, Dagim M. ;
Bunaye, Zerihun ;
Light, Robert P. ;
Agarwal, Rajiv .
HYPERTENSION, 2008, 52 (02) :249-255
[6]  
ALONI Y, 1983, MINER ELECTROL METAB, V9, P82
[7]  
Ammirati AL, 2007, PERITON DIALYSIS INT, V27, P340
[8]   Adynamic bone in patients with chronic kidney disease [J].
Andress, D. L. .
KIDNEY INTERNATIONAL, 2008, 73 (12) :1345-1354
[9]   Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation [J].
Andress, DL .
KIDNEY INTERNATIONAL, 2006, 69 (01) :33-43
[10]   Vitamin D in Chronic Kidney Disease More Questions Than Answers [J].
Anker, Stefan D. ;
von Haehling, Stephan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (07) :722-723